Kidney Week

Abstract: SA-PO0390

PREVENT Risk Scores as Predictors of Kidney Outcomes

Session Information

• CKM: Clinical - Epidemiology and Outcomes
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Cardiovascular-Kidney-Metabolic Health

• 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

• Rathi, Kartik Kumar, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Kartik Kumar Rathi, MD

• Singh, Ravinder, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Ravinder Singh, MS

• Hartsell, Sydney Elizabeth, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Sydney Elizabeth Hartsell, MD, MPH

• Melo, Isabelle, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Isabelle Melo, MD

• Wei, Guo, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Guo Wei, MS

• Throolin, Michael J., Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Michael J. Throolin, MS

• Boucher, Robert E., Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Robert E. Boucher

• Akramimoghadam, Farideh, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Farideh Akramimoghadam, MD

• Hamm, Kaila Madison, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Kaila Madison Hamm

• Nevers, Mckenna R., University of Utah Health, Salt Lake City, Utah, United States

Mckenna R. Nevers, MSc

• Shen, Jincheng, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Jincheng Shen, MS, PhD

• Beddhu, Srinivasan, Cardiovascular, Renal, and Metabolism Center. University of Utah, Salt Lake City, Utah, United States

Srinivasan Beddhu, MD

Background

PREVENT risk scores were developed by AHA to predict cardiovascular events and are widely used in clinical practice. It is unknown whether they could also predict kidney outcomes.

Methods

In a secondary analysis of a national cohort of veterans with T2D on metformin initiated on SGLT2i, GLP1 or insulin glargine for the first time between 01/01/2018 and 12/31/2021, we calculated PREVENT risk scores from age, sex, total cholesterol, HDL chloesterol, SBP, antihypertensive med use, A1C, eGFR, ACR (optional), smoking, BMI and zipcode in the entire cohort as well as in those with non-missing urinary albnumin-creatinine ratio (ACR). Follow-up was until 12/31/2023. Incidence of kidney progression composite (>50% eGFR decline, stage V CKD or ESKD) and kidney failure composite (stage V CKD or ESKD) were outcomes of interest and were estimated from three-year cumulative incidence function curves. .

Results

Baseline characteristics are summarized in Table. There were 1070 kidney progression and 409 kidney failure composite events. PREVENT scores predicted the incidence of both events in the entire cohort (with urine ACR optional for PREVENT score calculation) and in those with non-missing urine ACR (Figure).

Conclusion

PREVENT scores can be adopted to risk stratify for CKD progression and kidney failure irrespective of the availability of urine ACR in T2D population. Using a single scoring system to predict both ASCVD events and CKD progression/ kidney failure has the potential for wider adoption of kidney failure risk prediction in general clinical practice.

Funding

• NIDDK Support